Bristol-Myers Says Nimbus Wants To Keep New Drug For Itself
By Bryan Koenig ( September 16, 2021, 11:13 PM EDT) -- Bristol-Myers Squibb Co. and its subsidiary Celgene Corp. hit back against a biotechnology company's bid to avoid selling them a psoriasis drug the startup is developing, complaining that Nimbus Therapeutics LLC's lawsuit seeking to escape its promise to shed the anti-inflammatory is a backdoor way of attacking the pharma giant's completed acquisition of Celgene....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.